You are currently on the new version of our website. Access the old version .

13 Results Found

  • Review
  • Open Access
1,186 Views
26 Pages

9 November 2025

Atypical antipsychotics (AAPs) remain the most effective treatment to control irritability associated with autism spectrum disorder (ASD). Although there is no pharmaceutical treatment to target the core symptoms of ASD, AAPs reduce their severity. H...

  • Article
  • Open Access
1 Citations
3,655 Views
22 Pages

The LuBAIR™ Paradigm is a novel approach to ascribe meaning to behavioral expressions in advanced neurocognitive disorders when the reliability of a clinical assessment is limited. The meaning ascribed to each behavioral category was used to id...

  • Review
  • Open Access
184 Citations
31,158 Views
26 Pages

Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences

  • Marco Carli,
  • Shivakumar Kolachalam,
  • Biancamaria Longoni,
  • Anna Pintaudi,
  • Marco Baldini,
  • Stefano Aringhieri,
  • Irene Fasciani,
  • Paolo Annibale,
  • Roberto Maggio and
  • Marco Scarselli

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome (MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2...

  • Review
  • Open Access
2 Citations
5,016 Views
32 Pages

30 October 2025

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social and communication skills and restricted interests. It is associated with behavioural symptoms and/or comorbidities (e.g., attention deficit...

  • Article
  • Open Access
5 Citations
3,437 Views
27 Pages

16 October 2024

Prolonged use of atypical antipsychotics (AAPs) is commonly associated with increased cardiovascular disease risk. While weight gain and related health issues are generally considered the primary contributors to this risk, direct interference with mi...

  • Review
  • Open Access
73 Citations
9,464 Views
16 Pages

18 October 2017

Atypical antipsychotics (AAP) are the prevailing form of schizophrenia treatment today due to their low side effects and superior efficacy. Nevertheless, some issues still need to be addressed. First, there are still a large number of patients with t...

  • Article
  • Open Access
7 Citations
3,668 Views
17 Pages

Atypical Antipsychotics and the Human Skeletal Muscle Lipidome

  • Kyle J. Burghardt,
  • Kristen M. Ward,
  • Elani J. Sanders,
  • Bradley H. Howlett,
  • Berhane Seyoum and
  • Zhengping Yi

13 October 2018

Atypical antipsychotics (AAPs) are a class of medications associated with significant metabolic side effects, including insulin resistance. The aim of this study was to analyze the skeletal muscle lipidome of patients on AAPs, compared to mood stabil...

  • Article
  • Open Access
2,427 Views
18 Pages

Antioxidant Supplementation with ProCloSupp Protects Against Renal Toxicity of Atypical Antipsychotics in Rats: Implications for Safer Treatment Strategies

  • Tanja Grahovac,
  • Teodora Vidonja Uzelac,
  • Zorana Oreščanin Dušić,
  • Dušan Spasić,
  • Milica Mijović,
  • Aleksandra Nikolić-Kokić,
  • Čedo Miljević and
  • Duško Blagojević

28 October 2025

Atypical antipsychotics (AAP), including clozapine (Clo), aripiprazole (Ari), and risperidone (Ris), are widely used in psychiatry but can lead to kidney damage due to oxidative stress. This study investigated whether dietary supplementation with sel...

  • Article
  • Open Access
11 Citations
3,824 Views
11 Pages

Timing of Psychopharmacological and Nutritional Interventions in the Inpatient Treatment of Anorexia Nervosa: An Observational Study

  • Jacopo Pruccoli,
  • Martina Pelusi,
  • Giorgia Romagnoli,
  • Elisabetta Malaspina,
  • Filomena Moscano and
  • Antonia Parmeggiani

19 September 2021

This study aims to investigate possible different outcomes in the inpatient treatment of anorexia nervosa (AN) related to different timings of psychopharmacological and nutritional interventions. A retrospective observational study was conducted, inv...

  • Article
  • Open Access
2 Citations
3,416 Views
17 Pages

Profiling the Skeletal Muscle Proteome in Patients on Atypical Antipsychotics and Mood Stabilizers

  • Kyle J. Burghardt,
  • Griffin Calme,
  • Michael Caruso,
  • Bradley H. Howlett,
  • Elani Sanders,
  • Zaher Msallaty,
  • Abdullah Mallisho,
  • Berhane Seyoum,
  • Yue A. Qi and
  • Zhengping Yi
  • + 1 author

12 February 2022

Atypical antipsychotics (AAP) are used in the treatment of severe mental illness. They are associated with several metabolic side effects including insulin resistance. The skeletal muscle is the primary tissue responsible for insulin-stimulated gluco...

  • Review
  • Open Access
9 Citations
6,952 Views
20 Pages

Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma

  • Alexandre Vallée,
  • Jean-Noël Vallée and
  • Yves Lecarpentier

Glaucoma is a progressive neurodegenerative disease that represents the major cause of irreversible blindness. Recent findings have shown which oxidative stress, inflammation, and glutamatergic pathway have main roles in the causes of glaucoma. Lithi...

  • Article
  • Open Access
630 Views
14 Pages

The Impact of Copay Accumulators and Maximizers on Treatment Patterns, Adherence, and Costs Among Patients with Major Depressive and Bipolar Disorders Treated with Branded Therapies

  • Onur Baser,
  • Katarzyna Rodchenko,
  • Heidi C. Waters,
  • Matthew Sullivan,
  • Lixuan Wu,
  • Shuangrui Chen,
  • Madeline Shurtleff,
  • Cynthia Bigley and
  • Rashmi Patel

Copay accumulator (CA) and copay maximizer (CM) programs in the United States, which prevent manufacturer copay assistance from counting toward deductibles or out-of-pocket (OOP) maximums, are increasingly used, raising concerns about costs and outco...

  • Article
  • Open Access
4 Citations
5,002 Views
15 Pages

The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD): Changes in Preferred Treatment Strategies and Medications over 20 Years and Five Editions

  • Seung-Ho Jang,
  • Won-Myong Bahk,
  • Young Sup Woo,
  • Jeong Seok Seo,
  • Young-Min Park,
  • Won Kim,
  • Jong-Hyun Jeong,
  • Se-Hoon Shim,
  • Jung Goo Lee and
  • Kyung Joon Min
  • + 1 author

1 February 2023

Background. The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) is an expert consensus guideline for depressive disorder created in 2002, and since then, four revisions (2006, 2012, 2017, 2021) have been published. In this study...